Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluciclatide PET Imaging in Bevacizumab-Treated GBM
NCT01788280Phase 2Withdrawn
- Sponsor
- University of Utah
- Start
- Jan 2018
- Primary completion
- Jan 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluciclatide in glioblastoma multiforme (GBM), sponsored by University of Utah. Planned start Jan 2018; status: withdrawn.
02
Drugs
fluciclatide
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01788280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01788280.